Agmon-Levin Nancy, Gilburd Boris, Kivity Shaye, Katz Bat Sheva Porat, Flitman-Katzevman Iveta, Shoenfeld Netta, Paran Daphna, Langevitz Pnina, Shoenfeld Yehuda
Center for Autoimmune Diseases, Tel Hashomer, Israel.
Isr Med Assoc J. 2009 Jul;11(7):403-6.
Anti-ribosomal-P antibodies have been associated with central nervous system manifestations of systemic lupus erythematosus. However, inconsistencies in their prevalence and clinical correlations have become an obstacle to their use as a diagnostic marker of the disease. This lack of consistency might stem from several factors, such as the lag period between clinical manifestations and the time blood was drawn; or the different methods used for antibodies detection.
To evaluate three different enzyme-linked immunosorbent assay tests for the detection of anti-Rib-P Abs in patients with SLE and in normal controls.
Sera from 50 SLE outpatients and 50 healthy subjects were tested with three ELISA kits: Kit-1, using synthetic peptide comprising the 22 C-terminal aminoacids; Kit-2, using native human ribosomal proteins (P0, P1, P2); and Kit-3, which is coated with affinity-purified human ribosomal proteins. ELISA studies were performed according to the manufacturers' instructions.
The prevalence of anti-Rib-P Abs in SLE patients and controls was 30% vs. 0%, 17% vs. 21%, and 30% vs. 14% in kits 1-3 respectively. Anti-Rib-P Abs detected by Kit-1 correlated with the SLEDAI score (SLE Disease Activity Index). No correlation between prior CNS manifestations and anti-Rib-P Abs was observed.
A significant difference was documented between the ELISA kits used for the detection of anti-Rib-P Abs. A correlation was found between these antibodies (evaluated by Kit-1) and concurrent SLEDAI scores, in contrast to the lack of correlation with previous CNS manifestations. This supports the notion of "active serology" that is evaluated at the same time manifestations are present, as well as the need for standardization of laboratory assays in the future which will enable a better assessment of anti-Rib-P Abs presence and clinical significance.
抗核糖体P抗体与系统性红斑狼疮的中枢神经系统表现相关。然而，其患病率及临床相关性的不一致已成为将其用作该疾病诊断标志物的障碍。这种不一致可能源于多种因素，如临床表现与采血时间之间的间隔期；或用于抗体检测的不同方法。
评估三种不同的酶联免疫吸附测定法检测系统性红斑狼疮患者和正常对照中的抗核糖体P抗体。
用三种酶联免疫吸附测定试剂盒检测50例系统性红斑狼疮门诊患者和50例健康受试者的血清：试剂盒1，使用包含22个C末端氨基酸的合成肽；试剂盒2，使用天然人核糖体蛋白（P0、P1、P2）；试剂盒3，包被有亲和纯化的人核糖体蛋白。根据制造商的说明进行酶联免疫吸附测定研究。
试剂盒1 - 3中，系统性红斑狼疮患者和对照中抗核糖体P抗体的患病率分别为30%对0%、17%对21%、30%对14%。试剂盒1检测到的抗核糖体P抗体与系统性红斑狼疮疾病活动指数（SLEDAI）评分相关。未观察到既往中枢神经系统表现与抗核糖体P抗体之间的相关性。
用于检测抗核糖体P抗体的酶联免疫吸附测定试剂盒之间存在显著差异。发现这些抗体（通过试剂盒1评估）与同时期的SLEDAI评分相关，而与既往中枢神经系统表现缺乏相关性。这支持了在出现临床表现时同时评估“活性血清学”的观点，以及未来实验室检测标准化的必要性，这将有助于更好地评估抗核糖体P抗体的存在及其临床意义。
